NVK002
Pediatric Myopia (progression)
Phase 3Active
Key Facts
About Vyluma
Vyluma is a clinical-stage biotech founded in 2020, headquartered in Bridgewater, New Jersey. Its lead candidate, NVK002, is a low-dose atropine eye drop in late-stage development to slow the progression of pediatric myopia, positioning it to potentially be the first FDA-approved pharmaceutical treatment for this condition. The company has a broader pipeline targeting other prevalent vision disorders like presbyopia and night vision disturbance, leveraging its expertise in topical ophthalmic formulations. Vyluma operates as a private, pre-revenue company aiming to transform the standard of care in ophthalmology.
View full company profile